Compare Quest Diagnostics Inc (DGX) vs Global X Defense Tech ETF (SHLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Global X Defense Tech ETF — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while Global X Defense Tech ETF trades at $59.92 (market cap $6.29B). The key difference: Quest Diagnostics Inc is far larger — about 4.1× Global X Defense Tech ETF's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Global X Defense Tech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Global X Defense Tech ETF for 44 Days on average.
| DGX | SHLD | |
|---|---|---|
Market Cap | $25.48B | $6.29B |
Volume | 941,866 | 1,133,252 |
Sector | Health | Sector/Thematic |
52-Week High | $247.45 | $78.02 |
52-Week Low | $173.49 | $58.20 |
Typical Hold Time | 56 Days | 44 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
SHLD (Global X Defense Tech ETF) trades at $59.87, up 1.92% today, but technical indicators show a bearish trend with moving averages signaling strong selling pressure. The ETF focuses on defense technology with exposure to global defense firms, benefiting from increased defense spending trends. Recent institutional buying activity indicates growing investor interest in the defense sector.
The outlook for SHLD appears mixed - strong geopolitical tailwinds support defense spending growth, but technical weakness suggests near-term pressure. Key opportunities include exposure to rising global defense budgets, while risks involve sector volatility and geopolitical uncertainties affecting defense stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →
